Page 2482 - Williams Hematology ( PDFDrive )

2453
2452 Index Index 2453

effector cytokines in, 303 in platelet adhesion, 1834, 1847t, 1979 signaling pathways, 1069f
inappropriate response of, 304 in platelet aggregation, 1863–1864 spleen and production of, 1082
innate defects, 304 in platelet spreading, 1841–1842 thalidomide and, 334
platelet coagulant activity and, 1855 prothrombin and, 1854 Interferon (IFN)-α
sensors of the nucleotide-binding structure, 1184, 1860f, 1861–1862 adverse effects, 1314, 1459
oligomerization domain-like in thrombocytopenia, 2008 for chronic myelogenous leukemia, 1459
receptor family in, 298–300, 299f, variants, 1851 in chronic myelogenous leukemia,
300f, 301f von Willebrand factor binding to, 2168 1440–1441
sensors of the RIG-I-like helicase pathways Integrin α β receptor antagonists, 405–406, with cladribine, for mastocytosis, 977
IIb 3
in, 300–303, 302f 1855, 1995–1996, 2074t, 2077, for congenital dyserythropoietic anemia
toll-like receptors in. See Toll-like 2296. See also Abciximab type I, 566
receptors (TLRs) Integrin α β receptors, 1833–1834, 1861, for Erdheim-Chester disease, 1111
IIb 3
types, 293–294 2043–2044, 2043f for essential thrombocythemia, 1313t,
Innocent bystander mechanism, 830 Integrin α β (VLA-4), 261, 949, 950, 1185, 1314
4 1
Inosine triphosphatase, 701t 1737, 1977t for follicular lymphoma, 1647–1648
Inositol 1,4,5-triphosphate (IP ), 935, 1016, Integrin α β , 1138–1139 for hairy cell leukemia, 1553
3
4 7
1836, 1840 Integrin α β (GPIc*/IIa, fibronectin receptor, for lymphomatoid papulosis, 1689
5 1
INR (international normalized ratio), VLA-5, CD49e/CD29), 261, 1847t, in macrophages, 1064, 1069f
395–396, 396t 1858–1859t, 1865 in megakaryopoiesis, 1823
Insulin-like growth factor-1 (IGF-1), 487 Integrin α β (GPIc/IIa, laminin receptor, for mycosis fungoides, 1687
6 1
Insulin receptor substrates, 251 VLA-6, CD49f/CD29), 1847t, natural killer cells and, 1191
Integral membrane proteins. See Membrane 1858–1859t, 1865 in neutrophils, 933t
proteins, integral Integrin α β . See CD11b/CD18 (Mac-1, for polycythemia vera, 1298t, 1299
M 2
Integrin activation deficiency disease (LAD, Mo1, CR3, α β ) during pregnancy, 1459
M 2
LAD-1 variant), 1019t, 1024, 2060 Integrin α β (vitronectin receptor, CD51/ for primary myelofibrosis, 1329–1330
v 3
Integrin α β (GPIa/IIa, CD49b/CD29, CD61), 1847t, 1858–1859t, 1865, production, 309
2 1
VLA-2, collagen receptor), 2043f, 2044 for thrombocytopenia, 1824
1864–1865 Integrin β , 282–283, 1007 Interferon (IFN)-β, 1064, 1069f, 1823
1
characteristics, 1858–1859t Integrin β 2 Interferon (IFN)-β promoter stimulator 1
in collagen activation of platelets, in leukocyte adhesion, 282–283, 282f, 282t (IPS-I). See Mitochondrial antiviral
1879–1881, 1880f in lymphocytes, 1138–1139 signaling protein (MAVS)
gene mutations, 1864 in monocyte adhesion, 1059 Interferon (IFN)-γ, 291
in platelets, 1833, 1847t, 1851, 1858–1859t, in neutrophils, 2358 in aplastic anemia, 515
1864 Integrin β , 1851, 1885 for chronic granulomatous disease, 1012
3
structure, 1847t, 1864 Integrins, 66, 67t, 1858–1859t, 1861–1865 in inflammatory response, 1978
synthesis, 1847t in cell signaling, 250, 1015 in large granular lymphocytic leukemia,
Integrin α β (GPIa/IIa, CD49b/CD29, in hematopoietic stem cells, 260–261 1203
2 1
VLA-2, collagen receptor) inflammatory response and, 1083 in macrophage activation, 308, 1070t, 1085
deficiency, 2051 in leukocyte activation, 284 in megakaryopoiesis, 1823
Integrin α β (GPIIb/IIIa, fibrinogen in leukocyte adhesion, 282–283, 282f, 282t in natural killer cells, 1189
IIb 3
receptor, CD41/CD61), 1861–1864 monocytes and, 1059 in newborn, 107
abnormalities in neutrophil adhesion, 1007, 1007f in nitrogen metabolism, 1069f
in Glanzmann thrombasthenia. See neutrophils and, 1007 for primary myelofibrosis, 1329–1330
Glanzmann thrombasthenia in sickle cell disease, 764–765 in reactive thrombocytosis, 2036
select macrothrombocytopenias, 2047 in T-cell adhesion, 1184 in Th cells, 1180
activation, 1836, 1837, 1838f, 1860f, trafficking of hematopoietic stem cells and, in vaccines, 422
1863–1864 355 Interferon (IFN)-γR1 deficiency, 1231
biogenesis, 2043–2044, 2043f Integrin transmembrane complex, 1862f Interferon (IFN)-γR2 deficiency, 1231
in clot retraction, 1842 Intercellular adhesion molecules. See under γ-Interferon (IFN)-inducible protein, 288t
fibrinogen binding to, 1861 ICAM Interferon-regulated factor 8 (IRF8), 235t,
immune thrombocytopenia and, 2000 Interdigitating cells, 309. See also Dendritic 1231
inside-out activation, 1860f, 1862–1863, cells (DCs) Interferon regulatory factor 4 (IRF4),
1863f, 1883–1884 Interdigitating dendritic cell sarcoma, 1110 1171–1172, 1710, 1710f
outside-in signaling by, 1851, 1860f, Interferon (IFN) Interferon (INF) response factor (IRF), 297f,
1862–1863, 1863f, 1883–1884 in innate immune response, 303 298
platelet activation and, 2293 for primary myelofibrosis, 1329–1330 Interferon-stimulated gene 15 (ISG15), 1231

Kaushansky_index_p2393-2506.indd 2453 9/21/15 3:22 PM